CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Sean A. Mccarthy sold 14,340 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $20.60, for a total value of $295,404.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
CytomX Therapeutics, Inc. (NASDAQ CTMX) opened at $19.79 on Thursday. CytomX Therapeutics, Inc. has a 52 week low of $10.40 and a 52 week high of $24.67.
A number of research firms recently commented on CTMX. BidaskClub upgraded CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Bank of America reiterated a “buy” rating and set a $30.00 price objective (up previously from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. Jefferies Group set a $25.00 price objective on CytomX Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 25th. Wedbush began coverage on CytomX Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $26.00 price objective for the company. Finally, ValuEngine cut CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company’s stock. CytomX Therapeutics currently has a consensus rating of “Hold” and an average price target of $31.88.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.